Gene · 92521
Papers3,158
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,861 to 1,880 of 3,158
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| MERS-CoV: epidemiology, molecular dynamics, therapeutics, and future challenges. | Ann Clin Microbiol Antimicrob | 2021 | 33461573 | PubTator, text mining | PubMed |
| In silico validation of potent phytochemical orientin as inhibitor of SARS-CoV-2 spike and host cell receptor GRP78 binding. | Heliyon | 2021 | 33458435 | PubTator, text mining | PubMed |
| In silico exploration of novel protease inhibitors against coronavirus 2019 (COVID-19). | Inform Med Unlocked | 2021 | 33457495 | PubTator, text mining | PubMed |
| Bisindolylmaleimide IX: A novel anti-SARS-CoV2 agent targeting viral main protease 3CLpro demonstrated by virtual screening pipeline and in-vitro validation assays. | Methods | 2021 | 33453392 | PubTator, text mining | PubMed |
| Identification of existing pharmaceuticals and herbal medicines as inhibitors of SARS-CoV-2 infection. | Proc Natl Acad Sci U S A | 2021 | 33452205 | PubTator, text mining | PubMed |
| Dysregulation of Cell Signaling by SARS-CoV-2. | Trends Microbiol | 2021 | 33451855 | PubTator, text mining | PubMed |
| Whole-Genome Analyses Identifies Multiple Reassortant Rotavirus Strains in Rwanda Post-Vaccine Introduction. | Viruses | 2021 | 33445703 | PubTator, text mining | PubMed |
| Comprehensive in vivo secondary structure of the SARS-CoV-2 genome reveals novel regulatory motifs and mechanisms. | Mol Cell | 2021 | 33444546 | PubTator, text mining | PubMed |
| In-silico analysis of the inhibition of the SARS-CoV-2 main protease by some active compounds from selected African plants. | J Taibah Univ Med Sci | 2021 | 33437230 | PubTator, text mining | PubMed |
| Combination and tricombination therapy to destabilize the structural integrity of COVID-19 by some bioactive compounds with antiviral drugs: insights from molecular docking study. | Struct Chem | 2021 | 33437137 | PubTator, text mining | PubMed |
Mapping the SARS-CoV-2-Host Protein-Protein Interactome by Affinity Purification Mass Spectrometry and Proximity-Dependent Biotin Labeling: A Rational and Straightforward Route to Discover Host-Directed Anti-SARS-CoV-2 Therapeutics. | Int J Mol Sci | 2021 | 33430309 | PubTator, text mining | PubMed |
| A multi-pronged approach targeting SARS-CoV-2 proteins using ultra-large virtual screening. | iScience | 2021 | 33426509 | PubTator, text mining | PubMed |
| ORF3a of the COVID-19 virus SARS-CoV-2 blocks HOPS complex-mediated assembly of the SNARE complex required for autolysosome formation. | Dev Cell | 2021 | 33422265 | PubTator, text mining | PubMed |
| SARS-CoV-2 3D database: understanding the coronavirus proteome and evaluating possible drug targets. | Brief Bioinform | 2021 | 33416848 | PubTator, text mining | PubMed |
| Transcriptome of nasopharyngeal samples from COVID-19 patients and a comparative analysis with other SARS-CoV-2 infection models reveal disparate host responses against SARS-CoV-2. | J Transl Med | 2021 | 33413422 | PubTator, text mining | PubMed |
| The aging transcriptome and cellular landscape of the human lung in relation to SARS-CoV-2. | Nat Commun | 2021 | 33397975 | PubTator, text mining | PubMed |
| Backbone chemical shift assignments for the SARS-CoV-2 non-structural protein Nsp9: intermediate (ms - μs) dynamics in the C-terminal helix at the dimer interface. | Biomol NMR Assign | 2021 | 33392924 | PubTator, text mining | PubMed |
| SARS-CoV-2 therapeutics: how far do we stand from a remedy? | Pharmacol Rep | 2021 | 33389724 | PubTator, text mining | PubMed |
| Structural insights of key enzymes into therapeutic intervention against SARS-CoV-2. | J Struct Biol | 2021 | 33383190 | PubTator, text mining | PubMed |
| SARS-CoV-2 proteases PLpro and 3CLpro cleave IRF3 and critical modulators of inflammatory pathways (NLRP12 and TAB1): implications for disease presentation across species. | Emerg Microbes Infect | 2021 | 33372854 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/92521/papers?page=94